Date: 2015-01-21
Type of information: Nomination
Compound:
Company: Halozyme Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 21, 2015, Halozyme Therapeutics announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development. Dr. Bizzari was Group Head, Clinical Oncology Development at Celgene Corporation, a role he held since 2008. In this position, Dr. Bizzari was responsible for Celgene\'s clinical development and operations-statistics teams across the U.S., Europe and Asia/Japan and has overseen the development and approval of a number of leading oncology products including Revlimid® (lenalidomide), Vidaza® (azacitidine), Istodax® (romidepsin) and Abraxane® (nab-paclitaxel). In addition, he was Chairman of Celgene\'s hematology oncology development committee and a member of the company\'s management committee. Prior to his role at Celgene, Dr. Bizzari was the Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek® (rasburicase). Prior to that he was Vice President, Clinical Development Oncology for Sanofi-Synthelabo and had previously held the same role for Rhône-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France\'s National Cancer Institute and is a board member of Transgene. Jean-Pierre Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris.
Financial terms:
Latest news:
